Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Remembering Carl Boettcher, UNC carver and WWI emigre
Pieces of UNC’s history remain throughout campus, and some were created by a man who came to the United States for a better life. A...
Fri Apr 25, 2025

Chansky’s Notebook: Wide World of Sports
Jim Lampley’s memoir is out, and it really did happen. We had the official launch party Tuesday night at the Chapel Hill Country Club for...
Wed Apr 23, 2025

Spring at Carolina
Spring is in the air at the University of North Carolina, and the warmer temperatures bring plenty of favorite University traditions. Nothing feels more like...
Tue Apr 22, 2025

Sonja Haynes Stone’s legacy lives on at UNC's Stone Center
The Sonja Haynes Stone Center for Research in Black Culture and History aims to raise awareness of and appreciation for Black culture as one of...
Mon Apr 21, 2025